Also known as: BW301U; 2,4-diamino-6-(3,4-dichlorophenoxy)quinazoline
Piritrexim is a lipophilic antifolate that inhibits dihydrofolate reductase (DHFR) and was investigated for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis in immunocompromised patients. Mediocon Inc manufactures this API at its GMP-certified facility in Aurangabad, Maharashtra, India.
| Parameter | Specification |
|---|---|
| CAS Number | 3562-39-8 |
| Molecular Formula | C7H4N4O2 |
| Molecular Weight | 176.13 g/mol |
| Grade | IP / BP / USP |
| Category | Dihydrofolate Reductase Inhibitor / Antiprotozoal |
| Appearance | Yellow to orange crystalline powder |
| Solubility | Freely soluble in water, soluble in methanol, slightly soluble in ethanol |
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Batch No | PIR/24032026 |
| Mfg Date | MAR 2026 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Piritrexim — CAS 3562-39-8 (CAS 3562-39-8) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Piritrexim — CAS 3562-39-8 is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance